retatrutide trial news Medscape | Retatrutide, Eli Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the Trial of next-gen weight-loss drug

Based on current data, retatrutide appears to be the strongest weight loss injection studied so far

Presently the combination of a non-bile acid FXR agonist (GS-9674) + ACC inhibitor (GS-0976) is being investigated in an early phase II clinical trial.103 In an animal model of NASH, treatment with this combination therapy demonstrated a greater reduction in hepatic steatosis and genes associated with fibrosis than treatment with either agent alone.104 Future clinical trials will likely use combinations of agents that have already produced positive results individually

Mechanisms of Action of GLP-1

Orland and his colleagues looked at patient records from the TriNetX Global Health Research Network database, identifying more than 10,000 people who had been diagnosed with one of seven types of cancer breast, colorectal, kidney, liver, lung, pancreatic and prostate cancers

Some families may continue breastfeeding with healthcare guidance, while others may delay medication, reduce feeds, or wean